Literature DB >> 27347127

Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report.

Sang Mi Chung1, Seong Ji Choi1, Min Jung Kim1, Jung Yoon Choi1, Hong Jun Kim1, Suk-Young Lee1, Eun Joo Kang1.   

Abstract

Primary malignant pericardial mesothelioma (PMPM) is a rare tumor with poor prognosis. Surgery is the treatment of choice, but numerous cases are inoperable. For the treatment of inoperable or metastatic cases, systemic chemotherapy is required. However, a standard chemotherapeutic regimen for the treatment of pericardial mesothelioma has not yet been established. Chemotherapy involving pemetrexed and cisplatin has been actively used in the treatment of pleural or peritoneal mesothelioma, and may be considered for the treatment of PMPM. The present study reports the case of a patient with PMPM with lung metastasis who demonstrated a positive response to treatment with pemetrexed and cisplatin followed by pemetrexed maintenance chemotherapy, leading to prolonged progression-free survival for 21 months.

Entities:  

Keywords:  chemotherapy; cisplatin; malignant mesothelioma; pemetrexed; pericardium

Year:  2016        PMID: 27347127      PMCID: PMC4907022          DOI: 10.3892/ol.2016.4598

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  27 in total

1.  Malignant pericardial mesothelioma with response to chemotherapy.

Authors:  Nobukazu Fujimoto; Kenichi Gemba; Sae Wada; Katsuichiro Ono; Yasuhiro Fujii; Shinji Ozaki; Tetsuya Ikeda; Koji Taguchi; Tadayoshi Kunitomo; Takumi Kishimoto
Journal:  J Thorac Oncol       Date:  2009-11       Impact factor: 15.609

2.  Three-year survival after surgery for primary malignant pericardial mesothelioma: report of a case.

Authors:  Kishu Fujita; Mitsumasa Hata; Akira Sezai; Kazutomo Minami
Journal:  Surg Today       Date:  2013-02-14       Impact factor: 2.549

3.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

4.  An autopsy case of primary pericardial mesothelioma in arc cutter exposed to asbestos through talc pencils.

Authors:  Hiroshi Fujiwara; Takao Kamimori; Kenji Morinaga; Yoshiki Takeda; Norihiko Kohyama; Yoshihiro Miki; Kouki Inai; Satoru Yamamoto
Journal:  Ind Health       Date:  2005-04       Impact factor: 2.179

Review 5.  Pemetrexed safety and dosing strategy.

Authors:  Clet Niyikiza; Axel-R Hanauske; James J Rusthoven; A Hilary Calvert; Robert Allen; Paolo Paoletti; Paul A Bunn
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

6.  F-18 fluorodeoxyglucose PET/CT scanning in the diagnostic work-up of a primary pericardial mesothelioma: a case report.

Authors:  Piet Ost; Sylvie Rottey; Peter Smeets; Tom Boterberg; Barbara Stragier; Ingeborg Goethals
Journal:  J Thorac Imaging       Date:  2008-02       Impact factor: 3.000

Review 7.  [Malignant mesothelioma of the pericardium].

Authors:  A F De Rosa; G V Cecchin; M R Kujaruk; E G Gayet; L E Grasso; D G Rigou
Journal:  Medicina (B Aires)       Date:  1994       Impact factor: 0.653

8.  Malignant mesothelioma of the pericardium: a report of two different presentations.

Authors:  Pattarapong Makarawate; Narumol Chaosuwannakit; Jarin Chindaprasirt; Piti Ungarreevittaya; Surachat Chaiwiriyakul; Kosin Wirasorn; Chusak Kuptarnond; Kittisak Sawanyawisuth
Journal:  Case Rep Oncol Med       Date:  2013-08-21

9.  Pleural mesothelioma presenting as periumbilical metastasis: the first clinical documentation.

Authors:  R F Falkenstern-Ge; M Kimmich; S Bode-Erdmann; G Friedel; G Ott; M Kohlhäufl
Journal:  Case Rep Oncol Med       Date:  2013-04-18

Review 10.  Primary pericardial mesothelioma.

Authors:  Neyyir Tuncay Eren; A Ruchan Akar
Journal:  Curr Treat Options Oncol       Date:  2002-10
View more
  3 in total

1.  18F-fluorodeoxyglucose imaging of primary malignant pericardial mesothelioma with concurrent pericardial and pleural effusions and bone metastasis: A case report.

Authors:  Xiaohui Li; Rugang Lu; Youcai Zhao; Feng Wang; Guoqiang Shao
Journal:  Mol Clin Oncol       Date:  2018-04-12

2.  The Antemortem Diagnosis of Primary Malignant Pericardial Mesothelioma: A Multidisciplinary Evaluation.

Authors:  Kohei Shikano; Satoshi Hirano; Takuma Hiroishi; Noriko Hayama; Tetsuo Fujita; Hiroyuki Amano; Makoto Nakamura; Sukeyuki Nakamura; Hiroshi Tabeta; Shuji Ichinose; Osamu Uchida; Shinichiro Shimizu
Journal:  Intern Med       Date:  2018-04-27       Impact factor: 1.271

3.  Malignant Pericardial Mesothelioma Treated Using Volumetric Modulated Arc Therapy With a Simultaneous Integrated Boost.

Authors:  Cole Steber; Joshua Farris; Ryan T Hughes; Corbin A Helis; Tawfeq Naal; Jung W Kim-Shapiro; Travis Jacobson; Michael K Farris
Journal:  Adv Radiat Oncol       Date:  2020-09-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.